LIVING DOLL
agency: Digitas Health
brand: Arimidex
client: AstraZeneca
photo from left: Rita DiStefano Schuerman, account director • Mike Wilson, director, design technology • Andrew le Blanc, associate creative director • Ilana Grossman, VP, director of marketing
Surviving breast cancer is cause for celebration. And on behalf of the adjuvant breast cancer therapy Arimidex, Digitas Health found a way to let users celebrate life and courage by creating a place online where breast cancer survivors can gather and connect. CelebrationChain.com is the first—and still the only—branded social media site for pharma, says the agency.
Visitors to CelebrationChain.com can create a digital paper doll and send it to a friend to celebrate her life and courage in the face of breast cancer. Different clothing and hairstyle options allow users to customize the doll. All told, it's a poignant way for AstraZeneca to sponsor communication among the close-knit community of breast cancer patients and their advocates.
"AstraZeneca was really forward thinking in challenging us to come up with this," says Ilana Grossman. "All the design elements were grounded in the experience of the customer. These women, they're fighters. They celebrate life. They celebrate their survivorship." In sponsoring this site, Andrew le Blanc described the client as "brave" and "caring," adding, "Here's a company making an investment for a community."
That investment wasn't just emotional, but financial as well. For every doll created, AstraZeneca donates $1 to the nonprofit group Living Beyond Breast Cancer. Since the site's launch in October (Breast Cancer Month), more than 5,500 women have visited the site; they've made over 7,500 virtual dolls for friends and loved ones.
PREVIOUS AGENCY ‹‹ HOME ›› NEXT AGENCY
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.